Argo Biopharma focuses on developing innovative therapies that leverage advanced biopharmaceutical technologies. The company employs a proprietary platform that integrates cutting-edge techniques in drug discovery and development, aiming to address unmet medical needs in various therapeutic areas. Their pipeline includes a range of biologics and small molecules designed to target specific disease mechanisms, showcasing their commitment to precision medicine and tailored treatment approaches.

In addition to their drug development efforts, Argo Biopharma emphasizes the importance of scientific research and collaboration. The company utilizes state-of-the-art methodologies in molecular biology, biochemistry, and pharmacology to enhance the efficacy and safety of their products. By fostering partnerships with academic institutions and industry leaders, Argo Biopharma aims to accelerate the translation of scientific discoveries into viable therapeutic options, ultimately improving patient outcomes.

China

Argo Biopharma is a clinical stage biotech company that committed to developing a new generation of siRNA drugs to provide better treatments for global patients.
In the past two years, Argo biopharma has built a rich and differentiated pipeline of siRNA drug candidates for a wide range of indications, utilizing its industry-leading siRNA platform technology known as RADS (RNA molecules with superior Activity, Durability, and Safety).
Led by an experienced and professional team, Argo Biopharma has demonstrated scientific excellence in siRNA drug discovery and strong execution in advancing potential therapeutic products from discovery to clinical stage.

Argo Biopharma

Company Details